习勉
专长
一、基本情况
职称：主任医师、教授、博士生导师
职务：广东省食管癌研究所副所长
专业特长：食管癌、肝癌等胸腹部肿瘤的放射治疗
门诊时间：周二上午、下午（越秀院区），周四上午（黄埔院区）
主要研究方向：1、食管癌的放化综合治疗；2、肝癌的精准放疗。
二、个人简介
主要从事食管癌、肝癌等胸腹部肿瘤的放射治疗。2011年入选肿瘤防治中心优秀青年人才计划，2015年入选临床医学科学家培养计划，2016-2017年在美国M.D. Anderson肿瘤中心访问学习，为肿瘤防治中心食管癌单病种首席专家团队核心成员兼秘书，2021.12月起担任广东省食管癌研究所副所长。主持及参与食管癌、肝癌、肺癌多项临床试验，作为第一或通讯作者发表SCI论著50余篇，承担国家自然科学基金、广东省自然科学基金、广州市科技计划等多项课题。
三、工作经历
2007.08-2010.12 中山大学肿瘤防治中心放疗科，住院医师
2010.12-2015.12 中山大学肿瘤防治中心放疗科，主治医师
2015.12-2020.12 中山大学肿瘤防治中心放疗科，副主任医师
2016-2017 美国M.D. Anderson肿瘤中心，访问学者
2020.12-至今 中山大学肿瘤防治中心放疗科，主任医师
2023.12-至今 中山大学肿瘤防治中心放疗科，教授
四、学术任职
中国医药教育协会肿瘤放疗专委会常委；
广东省抗癌协会食管癌专业委员会常委；
广东省临床医学学会消化肿瘤综合治疗青年专业委员会副主委；
广东省器官医学与技术学会肝癌多学科综合治疗专委会副主委；
广东省肝脏病学会综合治疗专委会常委；
广东省抗癌协会肝癌专业委员会青委会常委；
广东省医药质量管理协会放射肿瘤学专委会常委；
中国抗癌协会食管癌专业委员会委员；
国际肝胆胰协会中国分会肝胆胰MDT专业委员会委员；
中华医学会/中国医师协会放疗专委会肝癌学组、食管癌学组委员。
五、近年已发表代表性第一/通讯作者论文
1. Chen B#, Liu S#, Zhu Y#, Wang R#, Cheng X, Chen B, Dragomir MP, Zhang Y, Hu Y, Liu M, Li Q*, Yang H*, Xi M*. Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab. Nat Commun. 2024;15(1):1919.
2. Zhu Y#, Wen J#, Li Q#, Chen B#, Zhao L#, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y*, Liu M*, Xi M*. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023;24(4):371-382.
3. Zhou S#, Wang Y#, Zhang R#, Zeng W#, Liu S, Liu S, Liu M, Yang H*, Xi M*. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. JAMA Netw Open. 2023;6(1):e2250965.
4. Chen R#, Liu Q#, Li Q#, Zhu Y#, Zhao L#, Liu S#, Chen B, Liu M, Hu Y, Lin T, Li J, Chen J, Lv Y, Fu J*, Xi M*, Yang H*. A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901). EClinicalMedicine. 2023;62:102118.
5. Cheng X#, Chen B#, Wang S#, Zhang J, Zhu J, Liu M, Liu S*, Xi M*. Association between lymphopenia and survival outcomes in esophageal carcinoma patients receiving combined immunotherapy and chemoradiotherapy. Oncologist. 2023;28(8):e606-e616.
6. Wang Y#, Li Q#, Zhang L, Liu S, Zhu J, Yang Y, Liu M, Zhang Y*, Xi M*. Efficacy and dose-response relationship of stereotactic body radiotherapy for abdominal lymph node metastases from hepatocellular carcinoma. Oncologist. 2023;28(6):e369-e378.
7. Wen J#, Fang S#, Hu Y#, Xi M#, Weng Z, Pan C, Luo K, Ling Y, Lai R, Xie X, Lin X, Lin T, Chen J, Liu Q*, Fu J*, Yang H*. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. EBioMedicine. 2022;86: 104371.
8. Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q, Cai L, Hu Y, Qiu B, Zhang L, Shen J, Yang Y, Liu M*, Xi M*. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun. 2021; 12(1): 4014.
9. Xu H, Lin M, Hu Y, Zhang L, Li Q, Zhu J, Wang S*, Xi M*. Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: Association with dosimetric parameters and patient outcomes. Oncologist. 2021; 26(3): e425-434.
10. Pan C, Wang Y, Liu Q, Hu Y, Fu J, Xie X, Zhang S*, Xi M*, Wen J*. Phenotypic profiling and prognostic significance of immune infiltrates in esophageal squamous cell carcinoma. OncoImmunology. 2021; 10(1): 1883890.
11. Liu S, Wen J, Yang H, Li Q, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Zhao L, Liu H, Hu Y, Liu M, Fu J*, Xi M*. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. Eur J Cancer. 2020;138: 113-121.
12. Zhou S, Yang H, Zhang J, Wang J, Liang Z, Liu S, Li Y, Pan Y, Zhao L, Xi M*. Changes in indoleamine 2,3-dioxygenase 1 expression and CD8+ tumor-infiltrating lymphocytes after neoadjuvant chemoradiation therapy and prognostic significance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020; 108(1):286-294.
13. Zhou S, Liu S, Lin C, Li Y, Ye L, Wu X, Jian Y, Dai Y, Ouyang Y, Zhao L, Liu M, Song L*, Xi M*. TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ. Oncogene. 2020; 39(18): 3710-3725.
14. Lan K, Zhu J, Zhang J, Zhou S, Yang Y, Feng Z, Zhang L, Wang S*, Xi M*. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2020; 149: 228-235.
15. Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: the impact of histology on recurrence patterns and outcomes. Ann Surg. 2019; 269(4): 663-670.
17. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma. Ann Surg. 2018; 268(2): 289-295.
18. Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A prognostic scoring model for the utility of induction chemotherapy prior to neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Oncol. 2017; 12(6): 1001-1010.
19. Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. 18F-FDG PET response after induction chemotherapy can predict who will benefit from subsequent esophagectomy after chemoradiotherapy for esophageal adenocarcinoma. J Nucl Med. 2017; 58(11): 1756-1763.
20. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity-modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017; 99(3): 667-676.
21. Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive partitioning analysis identifies pretreatment risk groups for the utility of induction chemotherapy prior to definitive chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2017; 99(2): 407-416.
22. Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017; 124(2): 318-324.
更新时间：2024.04.30
